Coccidioidomycosis presenting years after returning from travel.

After having traveled to California in 2017, a 26-year old Dutch man presented in 2020 with persisting cough and shortness of breath. Radiology showed cystic bronchiectasis with peri-bronchial consolidation in his right upper lobe. Laboratory studies in August 2021 showed an increased total IgE, specific Aspergillus IgE, eosinophilia and positive BAL culture for Coccidioides immitis/posadasii. After 6 weeks of itraconazole treatment for suspected allergic bronchopulmonary aspergillosis, symptoms persisted and respiratory cultures remained positive. The infection was cleared after a 6-month course of fluconazole. (max 75 words).

Preliminary Evaluation of Automated Speech Recognition Apps for the Hearing Impaired and Deaf.

OBJECTIVE: Automated speech recognition (ASR) systems have become increasingly sophisticated, accurate, and deployable on many digital devices, including on a smartphone. This pilot study aims to examine the speech recognition performance of ASR apps using audiological speech tests. In addition, we compare ASR speech recognition performance to normal hearing and hearing impaired listeners and evaluate if standard clinical audiological tests are a meaningful and quick measure of the performance of ASR apps. METHODS: Four apps have been tested on a smartphone, respectively AVA, Earfy, Live Transcribe, and Speechy. The Dutch audiological speech tests performed were speech audiometry in quiet (Dutch CNC-test), Digits-in-Noise (DIN)-test with steady-state speech-shaped noise, sentences in quiet and in averaged long-term speech-shaped spectrum noise (Plomp-test). For comparison, the app's ability to transcribe a spoken dialogue (Dutch and English) was tested. RESULTS: All apps scored at least 50% phonemes correct on the Dutch CNC-test for a conversational speech intensity level (65 dB SPL) and achieved 90-100% phoneme recognition at higher intensity levels. On the DIN-test, AVA and Live Transcribe had the lowest (best) signal-to-noise ratio +8 dB. The lowest signal-to-noise measured with the Plomp-test was +8 to 9 dB for Earfy (Android) and Live Transcribe (Android). Overall, the word error rate for the dialogue in English (19-34%) was lower (better) than for the Dutch dialogue (25-66%). CONCLUSION: The performance of the apps was limited on audiological tests that provide little linguistic context or use low signal to noise levels. For Dutch audiological speech tests in quiet, ASR apps performed similarly to a person with a moderate hearing loss. In noise, the ASR apps performed more poorly than most profoundly deaf people using a hearing aid or cochlear implant. Adding new performance metrics including the semantic difference as a function of SNR and reverberation time could help to monitor and further improve ASR performance.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.

INTRODUCTION: In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We explored tumor biopsy quality offered for mutation testing, different mutations distribution, and outcome with EGFR TKI. PATIENT AND METHODS: Clinical data from 8 regional hospitals were studied for patient and tumor characteristics, treatment and overall survival. Biopsies sent to the central laboratory were evaluated for DNA quality and subsequently analyzed for mutations in exons 18-21 of EGFR and exon 2 of KRAS by bidirectional sequence analysis. RESULTS: Tumors from 442 subsequent patients were analyzed. For 74 patients (17%) tumors were unsuitable for mutation analysis. Thirty-eight patients (10.9%) had EGFR mutations with 79% known activating mutations. One hundred eight patients (30%) had functional KRAS mutations. The mutation spectrum was comparable to the Cosmic database. Following treatment in the first or second line with EGFR TKI median overall survival for patients with EGFR (n = 14), KRAS (n = 14) mutations and wild type EGFR/KRAS (n = 31) was not reached, 20 and 9 months, respectively. CONCLUSION: One out of every 6 tumor samples was inadequate for mutation analysis. Patients with EGFR activating mutations treated with EGFR-TKI have the longest survival.

Health status in routine clinical practice: validity of the clinical COPD questionnaire at the individual patient level.

BACKGROUND: There is a growing interest to use health status or disease control questionnaires in routine clinical practice. However, the validity of most questionnaires is established using techniques developed for group level validation. This study examines a new method, using patient interviews, to validate a short health status questionnaire, the Clinical COPD Questionnaire (CCQ), at the individual patient level. METHODS: Patients with COPD who visited an outpatient clinic completed the CCQ before the consultation, and the specialist physician completed it after the consultation. After the consultation all patients had a semi-structured in-depth interview. The patients' CCQ scores were compared with those of the treating clinician, and with mean scores from 5 clinicians from a pool of 20 who scored the CCQ after reading the transcript of the in-depth interviews only. Agreement was assessed using Lin's concordance correlation coefficient (CCC), and Blant and Altman plots. Interviews with patients with low agreement were reviewed for possible explanations. RESULTS: A total of 44 COPD patients (32 male, mean age 66 years, FEV1 45% of predicted) participated. Agreement between the patients' CCQ scores and those of the treating clinicians (CCC = 0.87) and the mean score of the reviewing clinicians (CCC = 0.86) was very high. No systematic error was detected. No explanation for individuals with low agreement was found. CONCLUSION: The validity of the CCQ on the individual patient level, as assessed by these methods, is good. Individual health status assessment with the CCQ is therefore sufficiently accurate to be used in routine clinical practice.

Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program.

OBJECTIVE: To investigate whether a 12-week pedometer-based exercise counseling strategy is feasible and effectively enhances daily physical activity in outclinic Chronic Obstructive Pulmonary Disease (COPD) patients who do not participate in a rehabilitation program in a controlled way. METHODS: 35 outclinic COPD patients (21 males, mean age 62 years, GOLD I-III, mean FEV(1)% predicted 64.7) were randomized for a 12-week individual pedometer-based exercise counseling program promoting daily physical activities or usual care. Daily physical activity (DigiWalker SW-200), physical fitness, health-related quality of life, self-efficacy, fatigue, depression and motivation to be physically active were assessed before and after the intervention. RESULTS: After the intervention, COPD patients in the exercise counseling group showed a significant increase in their mean number of steps/day (from 7087 to 7872), whereas the usual care group showed a decrease (from 7539 to 6172). Significant differences favoring the exercise counseling group were demonstrated in arm strength, leg strength, health-related quality of life and intrinsic motivation to be physically active. CONCLUSION: Our study shows that a 12-week pedometer-based exercise counseling strategy is feasible and effectively enhances daily physical activity, physical fitness, health-related quality of life and intrinsic motivation in outclinic COPD patients who do not participate in a rehabilitation program. PRACTICE IMPLICATIONS: The feasibility of our exercise counseling strategy is good and patients were motivated to participate.